Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Novozymes A/S (NSIS-B.CO)
Bagsvaerd, DK
Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends internationally, serving markets in Denmark, the rest of Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America. Novozymes' diverse portfolio includes protein solutions for the food and beverage sector, alongside a comprehensive suite of cleaning and hygiene offerings for industrial, medical, and household applications, such as drain openers, septic tank treatments, ware washing, and professional laundry. In agriculture, they supply solutions for various crops like corn, cotton, soybeans, and wheat, focusing on bioyield and biocontrol, in addition to animal health and nutrition products and aquaculture systems for warm water species. The company actively supports sustainable industrial processes with contributions to bioenergy (including ethanol, biodiesel, renewable diesel, biogas, and wastewater treatment), biorefining (encompassing fiber modification, bleach boosting, deposit control, starch modification, carbon capture), and applications for textiles and leather. Their extensive range of enzyme solutions, such as lipases, proteases, oxidoreductases, and carbohydrases, are crucial for processes like corn and wheat separation, liquefaction, and saccharification. Furthermore, Novozymes addresses human health with solutions targeting brain, oral, protective, immune, and gastrointestinal well-being, while also engaging in areas like biocatalysis, cell culture, and diagnostics.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.56% | +1.62% | -1.02% | -5.75% | -10.17% | -4.99% | -13.73% | +3.37% | -15.90% | +18.93% | +1,056.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 10 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+8.5% ★ Q1'26: +3.9% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+86.6% ★ Q1'26: +7.5% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+17.6% Q1'26: +7.9% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+19.5% ★ Q1'26: +24.0% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+1.9% Q1'26: +6.0% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+1.6% Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×16.20× Q1'26: 2.99× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 14 Rev. Ana. 9 EPS Ana. |
Dec 2027 16 Rev. Ana. 11 EPS Ana. |
Dec 2028 14 Rev. Ana. 7 EPS Ana. |
Dec 2029 9 Rev. Ana. 2 EPS Ana. |
Dec 2030 13 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
17.90B
est: 3.04B (+487.8%)
|
3.83B
est: 29.45B (-87.0%)
|
4.15B
est: 31.32B (-86.7%)
|
33.17B
32.83B – 34.06B
+5.9% YoY
|
35.57B
34.38B – 36.86B
+7.2% YoY
|
38.17B
37.32B – 39.38B
+7.3% YoY
|
41.08B
40.17B – 42.39B
+7.6% YoY
|
43.98B
43.00B – 45.38B
+7.1% YoY
|
| EBITDA |
5.47B
est: 930.12M (+488.1%)
|
1.04B
est: 9.00B (-88.5%)
|
1.39B
est: 9.57B (-85.5%)
|
10.13B
10.03B – 10.40B
+5.9% YoY
|
10.87B
10.50B – 11.26B
+7.2% YoY
|
11.66B
11.40B – 12.03B
+7.3% YoY
|
12.55B
12.27B – 12.95B
+7.6% YoY
|
13.44B
13.14B – 13.86B
+7.1% YoY
|
| EBIT |
4.08B
est: 661.71M (+516.8%)
|
493.11M
est: 6.40B (-92.3%)
|
811.09M
est: 6.81B (-88.1%)
|
7.21B
7.13B – 7.40B
+5.9% YoY
|
7.73B
7.47B – 8.01B
+7.2% YoY
|
8.29B
8.11B – 8.56B
+7.3% YoY
|
8.93B
8.73B – 9.21B
+7.6% YoY
|
9.56B
9.35B – 9.86B
+7.1% YoY
|
| Net Income |
3.02B
est: 480.07M (+530.0%)
|
305.56M
est: 5.51B (-94.5%)
|
583.16M
est: 6.65B (-91.2%)
|
6.45B
5.43B – 7.47B
-3.1% YoY
|
7.16B
5.97B – 8.36B
+11.0% YoY
|
8.52B
7.98B – 9.06B
+19.0% YoY
|
10.22B
9.92B – 10.64B
+19.9% YoY
|
11.23B
10.90B – 11.69B
+9.9% YoY
|
| SGA |
3.32B
est: 593.87M (+459.7%)
|
764.90M
est: 5.74B (-86.7%)
|
911.11M
est: 6.11B (-85.1%)
|
6.47B
6.40B – 6.64B
+5.9% YoY
|
6.94B
6.71B – 7.19B
+7.2% YoY
|
7.44B
7.28B – 7.68B
+7.3% YoY
|
8.01B
7.83B – 8.27B
+7.6% YoY
|
8.58B
8.39B – 8.85B
+7.1% YoY
|
| EPS |
10.95
est: 1.02 (+971.5%)
|
0.67
est: 11.74 (-94.3%)
|
1.25
est: 14.17 (-91.2%)
|
15.09
11.64 – 16.00
+6.6% YoY
|
16.71
12.78 – 17.90
+10.7% YoY
|
18.46
17.10 – 19.40
+10.5% YoY
|
21.88
21.25 – 22.79
+18.5% YoY
|
24.04
23.35 – 25.04
+9.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 2/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ester Baiget | President & Chief Executive Officer | 31M | female |
| Rainer Lehmann | Executive Vice President & Chief Financial Officer | 16M | male |
| Anders Lund | Chief Operating Officer | 6M | male |
| Tina Sejersgaard Fano | Executive Vice President of Planetary Health Biosolutions | 6M | female |
| Morten Enggaard Rasmussen | Executive Vice President of People & Stakeholder Relations | — | male |
| Tobias Cornelius Bjorklund | Head of Investor Relations | — | male |
| Tue Micheelsen | President of Novonesis North America & Head of Global Consumer Health | — | male |
| Andrew Taylor | Executive Vice President of Food & Beverage Biosolutions | — | male |
| Claus Crone Fuglsang | Chief Scientific Officer | — | male |
| Henrik Joerck Nielsen | EVice President of Human Health Biosolutions and Strategy & Integration | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NSIS-B.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
